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1. Introduction 
Amyloidosis is a disease resulting from extra cellular accumulation of insoluble proteins in 
different organs and blood vessels. The term systemic amyloidosis is used to define applied 
to a variety of disease entities with a wide morphological and clinical spectrum (1). All 
amyloid proteins have biophysically comparable features (congo red binding, green color in 
polarized light, fibrillar appearance on electron microscopy) (2). Depending on the organ 
involvement type and amount, amyloid may cause progressive and life threatening organ 
dysfunction (3). There are numerous distractive types of amyloid fibrils are now known  
(4-7). The main protein types leading to amyloidosis are shown in Table 1. 
In children, the most common form of amyloidosis is reactive AA amyloidosis due to 
hereditary periodic fever (HPF) syndromes. The genetics causes of these syndromes derive 
from defects of the innate immunity and have been well defined at the clinical and 
genetically level are. Familial Mediterranean Fever (FMF), Hyperimmunoglobulinaemia D 
and periodic fever syndrome (HIDS), tumor necrosis factor (TNF) receptor-associated 
periodic syndrome (TRAPS) and the cryopyrin-associated periodic syndrome (CAPS), 
which encompasses Muckle- Wells syndrome (MWS), familial cold autoinflammatory 
syndrome (FCAS), and chronic infantile neurological cutaneous and articular syndrome 
(CINCA). 
Juvenile idiopathic arthritis (JIA) is one of the more common chronic diseases of childhood, 
with a prevalence of approximately 1 per 1,000 (8). The most dramatic systemic 
inflammation is seen in patients with systemic JIA. This disorder is somewhat different from 
the other forms of JIA. A role for T cell and antigen –specific responses and many of the 
manifestations seem to be caused by the overproduction of IL-6 (figure 1). The prevalence of 
secondary amyloidosis in JIA varies between 1% and 10% (9-11). Risk for amyloidosis in 
systemic JIA patients is associated with a long-lasting inflammation (12). Although its 
frequency is dramatically decreasing, probably in relation with a more active DMARD 
treatment policy (13) Cantarini et al (14) suggest that MEFV may represent a triggering 
factor for the development of inflammatory state in systemic JIA, that may be an 
autoinflammatory disorder in itself rather than a subtype of JIA. Amyloid A precursor, 
serum amyloid A (SAA), is a major acute phase reactant, therefore being raised in chronic 
inflammatory diseases (15,16).  
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Amyloid protein  Precursor protein  
AA  Serum amyloid A protein  
AL  Monoclonal Ig light chains  
AH  Monoclonal Ig light chains  
Aβ2M  β2-microglobulin  
AFib  Fibrinogen α-chain  
Acys  Cystatin C  
ALys  Lysozyme  
AApoAI Apolipoprotein AI  AApoAI Apolipoprotein AI  
AApoAII Apolipoprotein AII  AApoAII Apolipoprotein AII  
ATTR Transthyretin  ATTR Transthyretin  
AGel Gelsolin  AGel Gelsolin  
Table 1. Amyloid proteins and their precursors  
 
Clinical Effects:
Fever, Anemia, Increased acute phase reactants, thrombocytosis and poor growth
Immunological Effects:
Impaired NK cells, B cell growth, Plasma cell expansion
End organ Effects:
Arthritis, Amyloidosis
IL-6
 
Fig. 1. IL-6 is an important mediator in systemic JIA and causes many different 
manifestation 
AL amyloidosis is generally seen in the elderly. β2-microglobulin amyloidosis (Aβ2M 
amyloidosis) is seen in patients with renal failure. AFib and ACys amyloidoses are 
hereditary, autosomal dominant, and late-onset diseases having rarely been reported in 
children (6,7). Apart from the AL and AA amyloidosis, the kidney is also rarely affected by 
hereditary type amyloidoses, such as amyloid of fibrinogen (AFib), Apolipoprotein AI 
(AApoAI), and lysozymederived (ALys) amyloidosis (17). 
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This review discusses the pathogenesis, common causes clinical manifestations, diagnosis, 
and treatment of amyloidosis in children. 
2. Pathogenesis 
Amyloidosis is a general denominator for a group of diseases that are characterized by 
extracellular deposition of fibrils of aggregated proteins (18). These fibrils consist of 
polymers in a β sheet configuration of a precursor protein. SAA is a precursor protein in 
reactive amyloidosis and an acute phase protein that is mainly produced in the liver upon 
stimulation with various pro-inflammatory cytokines, interleukin (IL)-1β, tumor necrosis 
factor (TNF)-α, and IL-6. It is found in plasma as an apolipoprotein of HDL cholesterol. 
During active inflammation serum concentrations beyond 1000 mg/l can be reached, 
which is 1000-fold higher than the constitutional concentration (19-21). Although the size 
of the SAA protein produced by the liver is 104 amino acids, amyloid fibrils found in 
patients with AA amyloidosis mainly consist of an accumulation of the 76 N-terminal 
amino acids of this protein, although proteins of different length have been reported 
(22,23). Polymerization of SAA into amyloid fibrils requires removal of the C-terminal of 
the AA protein (24). The C-terminal portion of SAA is cleaved off by macrophages. The 
persistent augmentation of an inflammatory pathway through the innate immune system 
might be crucial in the deposition of the amyloid protein leading to the clinical picture of 
renal amyloidosis (25). 
3. Clinical manifestations  
Amyloidosis is a multisystemic disease. Therefore, clinical manifestations vary widely, 
nonspecific and depending on the involved organ(s) and the amount of amyloid fibrils 
deposited. Several organs can be affected by AA amyloidosis, but the kidneys are most 
frequently involved.  
Reactive amyloidosis usually presents as proteinuria with or without renal impairment. 
Renal involvement is found in >90% of patients (26). In addition, other organs including 
heart, peripheral nerves, thyroid, gastrointestinal system, and bone marrow can be involved 
by the type of amyloid fibrils. Clinically, it is difficult to distinguish AA and AL amyloidosis 
from each other because of overlapping clinical presentations. Gastrointestinal involvement 
is seen in about 20% of patients with reactive amyloidosis, and may present as diarrea, 
malabsorption or gastrointestinal pseudo-obstruction (23,26).Amyloidotic goitre, 
hepatomegaly, splenomegaly and polyneuropathy are less frequently encountered features 
of reactive amyloidosis (27,28). Amyloidosis can cause bleeding diathesis due to factor X 
deficiency, liver disease, or infiltration of blood vessels (29). In contrast to other types of 
amyloidosis, cardiac involvement is rare in reactive amyloidosis (30). Involvement of heart 
and kidneys are the most important predictors affecting survival (25). Infiltration of amyloid 
fibrils may cause enlargement of muscles and arthropathy. The clinical manifestations of 
Aβ2M amyloidosis include carpal tunnel syndrome, bone cysts, spondyloarthropathy, 
pathologic fractures, and swollen painful joints (31). 
In kidney involvement; asymptomatic proteinuria is the most common initial presentation, 
gradually progressing to nephrotic syndrome and/or renal dysfunction. In the series 
reported by the Turkish FMF study group, the presenting clinical features of the patients 
with amyloidosis secondary to FMF were as follows: 32% proteinuria, 40% nephrotic 
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syndrome, and 28% chronic renal failure (24). The patients having glomerular amyloid 
deposition are more common and have a poorer prognosis than patients having vascular 
and tubular amyloid deposition in rheumatoid arthritis-related AA amyloidosis (32). Nishi 
et al. (33) showed that 10–30% of patients with renal amyloidosis might have only mild 
proteinuria and normal renal function. 
4. Diagnosis 
Suspicion is essential in subjects having an underlying disease with a potential to cause 
amyloidosis. Amyloidosis should be suspected typically in a patient who presents with 
proteinuria. In fact, in patients who are candidates for this complication, secondary 
amyloidosis should also be considered in the differential diagnosis of cardiomyopathy, 
peripheral neuropathy, hepatomegaly, or in the presence of symptoms related to the 
gastrointestinal tract. The diagnosis of amyloidosis is based on the demonstration of 
amyloid fibrils in the biopsy of the involved tissue. Renal, rectal or abdominal fat biopsies 
may also reveal amyloid deposition. The deposited amyloid fibrils are extracellular, 
eosinophilic, and metachromatic on light microscopy. Congo red staining is necessary for 
diagnosis. Amyloid fibrils appear faintly red on Congo red staining and show the 
characteristic apple-green birefringence under polarized light. Actually, infiltrative renal 
diseases including amyloidosis must be considered in the differential diagnosis of all 
patients having chronic kidney disease and normal or large sized kidneys. AA amyloidosis 
can also be diagnosed using serum amyloid P component scintigraphy (34).  
5. Underlying causes of secondary amyloidosis 
5.1 Familial mediterranean fever 
FMF is characterized by recurrent periodic fever episodes and serositis along with an 
increased acute inflammatory response (35,36). FMF is the overall most common 
autoinflammatory disease and has prevalences as high as 1/ 1,000–1/250 among Jews, 
Turks, Armenians, and Arabs (37). The most seri o u s complication of the disease is the 
development of AA type amyloidosis, first diagnosed by Mamou and Cattan in 1952 (38). 
This is due to caused by accumulation of amyloid fibrils in the extracellular spaces of 
various organs and tissues, most notably the kidneys, liver and spleen, leading to organ 
failure (39). Several genetic and environmental factors modify the risk for reactive 
amyloidosis (23). 
The typical manifestation of amyloidosis in a FMF patient is defined with nephrotic ranged 
proteinuria, and uremia, arising from deposition of amyloid fibrils in the kidneys. The 
phenotypic features of the disease and the frequency of amyloidosis differs among various 
ethnic groups and it was emphasized by several authors that Turks have more severe 
disease with a higher incidence of amyloidosis (40). 
FMF is caused by a mutation in the MEFV (pyrin) gene. Although some mutations have 
been described, the four most prevalent ones (M694V, M680I, M694I and V726A) account for 
over 80% of cases (41-43).  
Pyrin expressed primarly in the innate immune system (granulocyte, dendritic cell, etc.). 
Both pyrin and a related gene, cryopyrin, contain an N- terminal domain that encodes a 
death domain –related structure, now known as the pyrin domain, or PyD. Both pyrin and 
cyropyrin interact through their PyDs with a common adaptor protein, apoptotic speck 
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protein (ASC). ASC itself participates in apoptosis, recruitment, and activation of pro-
caspase-1 (also named as IL-1β converting enzyme) and nuclear factor –kB, a transcription 
factor involved in initiation and resolution of the inflammatory response (44). 
Wild –type pyrin has been found either to inhibit or accentuate caspase-1 activity and it is 
key molecule in the inflammasome. The net effect of pyrin, and the molecular mechanisms 
of FMF-associated mutations, remains controversial. This results in clinical attacks of 
inflammation in the form of fever and serositis along with increased acute-phase reactants 
(APRs) (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and SAA). The 
continuous elevation of these APRs during and even between attacks predisposes to the 
development of AA systemic amyloidosis.  This inflammatory state is what probably results 
in the variety of problems related to clinical inflammation observed in patients with FMF 
(25). If the child has not been treated properly and if secondary amyloidosis develops, 
urinalysis will reveal proteinuria (45). If proteinuria is not diagnosed, it will progress to full-
blown nephrotic syndrome. 
Not all FMF patients having amyloidosis, suggests the presence of other contributing 
factors. The role of genetic background was established by comparing the incidence of 
amyloidosis in Jewish patients from different ethnic origins. Apart from ethnicity, 
several other genetic risk factors have been defined. The M694V mutation has been 
shown to be a strong risk factor of developing amyloidosis in different ethnic groups (46-
49). We studied in 308 patients with FMF and detected amyloidosis 8 (2.6% ) patients 
with amyloidosis homozygous for the M694V mutation had earlier onset and, a more 
severe course (50).  
Another factor that modulates the risk of developing amyloidosis is the SAA1 gene 
haplotype. Single nucleotide polymorphisms in the gene coding for SAA define 3 
haplotypes: 1.1, 1.3 and 1.5. Patients with a 1.1/1.1 genotype have an increased risk for 
amyloidosis of 3–7-fold, independent of MEFV genotype (40,51). In addition, there is 4.5–6-
fold increased risk of developing amyloidosis in affected family members of FMF patients 
who have already developed amyloidosis (36,52). 
Colchicine treatment has changed the course of FMF by both reducing attack frequency 
and severity and preventing amyloidosis. Goldinger first described its effectiveness in 
1972 and since then colchicine became the drug of choice for FMF (53). Colchicine, an 
alkaloid, binds to β-tubulin hindering its polarization with consequent defective transfer 
and mitosis, inhibition of neutrophil chemotaxis, and reduced expression of adhesion 
molecules (24). 
Before the advent of colchicine, amyloidosis was relatively frequent. It occurred in up to 
60%–75% of patients over the age of 40, and the incidence varied among different ethnic 
groups (54). Akse Onal et al. (37) observed a dramatic decrease of secondary amyloidosis in 
Turkey. They think that the decrease of the rate of amyloidosis in childhood is due to better 
education of Turkish physicians on the subject and the improvement in the infectious milieu 
of young children. 
5.2 TNF receptor-associated periodic syndrome 
This dominantly inherited disorder was first described in a large family of Irish/Scottish 
ancestry and hence named familial Hibernian fever (55). It is the second most common 
periodic fever disorder. Dominantly inherited heterozygous mutations in TNFRSF1A, 
encoding the TNF receptor 1 cause TRAPS (56). Because all known mutations are in the 
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extracellular domain of the receptor, it has been hypothesized that TRAPS mutations 
interfere with the shedding of the TNF receptor (57). Impaired receptor shedding might then 
lead to repeated signaling and prolongation of the immune response. TNFRSF1A mutations 
cause to reduced cell surface expression of mutant receptors. This would lead to deficiency 
of anti inflammatory soluble TNF receptors. Patients experience recurrent, often prolonged 
fevers that can be accompanied by severe abdominal pain, pleurisy, arthritis a migratory 
skin rash with underling fasciitis and/or periorbital edema (58,59). The age of onset varies 
widely, but most patients become symptomatic within the first decade of life. Attacks persist 
for a minimum of 3 days, but usually last longer, up to several weeks (60,61). Some TRAPS 
patients eventually develop systemic AA amyloidosis. An estimated 14%–25% of TRAPS 
patients develop reactive amyloidosis (57,62). The risk of amyloidosis appears to be greater 
among patients with cysteine mutations (63). Affected family members of TRAPS patients 
with amyloidosis are at increased risk and it is advisable to screen urine samples at regular 
intervals for proteinuria. Treatment depends on the severity of the disease. For patients with 
infrequent attacks and normal SAA, prednisone during attacks may be effective (61). For 
patients with more severe disease, etanercept or adalimumab as anti-TNF agents were 
found to be effective. IL-1 receptor antagonist has also shown to be effective in non-
responsive patients (64). 
5.3 Cryopyrin-associated periodic syndrome 
Cryopyrin-associated periodic syndromes (CAPS) are a group of rare autoinflammatory 
diseases including familial cold urticaria (FCAS), Muckle-Wells syndrome (MWS), and 
chronic infantile neurologic cutaneous articular syndrome (CINCA), also known as neonatal 
onset multisystem inflammatory disease (NOMID). CAPS are all caused by mutations in 
CIAS1 encoding cryopyrin, which is a component of the IL-1β inflammasome (56). These are 
all transmitted in an autosomal-dominant fashion. FCAS is characterized by recurrent, short 
attacks of fever, urticarial skin rash, arthralgia and conjunctivitis after exposure to cold. The 
peak of the attack occurs at 6–8 h and lasts up to 24 h. Amyloidosis is a rare complication of 
FCAS (2–4%) (65). In MWS, the typical attack includes fever, rash, arthralgia, arthritis, 
myalgia, headaches, conjunctivitis, episcleritis, and uveitis lasting up to 3 days. Progressive 
sensorineural hearing loss develops in the second and fourth decades. Amyloidosis 
develops in 25% of the cases (66). The onset of CINCA-NOMID is at or within several weeks 
of birth. It is characterized by urticaria-like rash, fever, chronic aseptic meningitis, eye 
findings including conjunctivitis, uveitis, and papillitis of the optic nerve. Half of patients 
develop a severe arthropathy.Patients have typical morphological changes of short stature, 
frontal bossing, macrocephaly, saddle nose, short, thick extremities with clubbing of fingers, 
and wrinkled skin. If untreated, 20% die by age 20 years, and others develop amyloidosis 
(67). [In CINCA and MWS, corticosteroid therapy can be useful in selected patients. Anti-IL-
1 agents are very effective in all CAPS patients. 
5.4 Hyper IgD syndrome 
HIDS was identified as a separate disease entity in 1984 (68). It is inherited as an autosomal 
recessive trait. HIDS is caused by mutations in the MVK gene, on chromosome 12, which 
encodes mevalonate kinase. Mutations associated with HIDS lead to markedly reduced 
mevalonate kinase enzymatic activity. Excessive production of pro inflammatory cytokines 
by HIDS mononuclear cells may result from excessive accumulation of mevalonic acid 
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substrate, recent data support an alternative hypothesis related to deficiencies in nonsterol 
isoprenoids synthesized through the mevalonate pathway. This is characterized by fever, 
arthralgia, abdominal pain, diarrhea, maculopapular rash, and lymphadenopathy lasting 3–
7 days. An attack can be provoked by minor trauma, vaccination or stress. The attacks 
usually recur every 4–6 weeks, but there is considerable inter- and intraindividual variation. 
Secondary amyloidosis has been reported in 3% of the patients, which is rarer than that 
reported for the other monogenic autoinflammatory syndromes (69). Corticosteroids are 
ineffective in preventing or treating attacks. A number of treatments have been tried 
including biologics. Simvastatin used because of its inhibition of HMG-CoA reductase, the 
enzyme proximal to mevalonate kinase in the isoprenoid pathway (70).  
5.5 Deficiency of the Interleukin-1 receptor antagonist 
DIRA is a rare autosomal recessive autoinflammatory disease caused by mutations affecting 
the gene IL1RN encoding the endogenous IL-1 receptor antagonist (9, 10). Children with 
DIRA present with strikingly similar clinical features including systemic inflammation in 
the perinatal period, bone pain, characteristic radiographical findings of multifocal sterile 
osteolytic bone lesions, widening of multiple anterior ribs, periostitis, and pustular skin 
lesions. Amyloidosis associated with this syndrome have been reported yet. 
5.6 Juvenile idiopathic arthritis 
Juvenile idiopathic arthritis is the most common rheumatic disease of childhood. The 
diagnostic criteria requires a child younger than 16 years of age with arthritis for at least 6 
weeks’ duration with exclusion of other identifiable causes of arthritis. Juvenile idiopathic 
arthritis has been classified into seven subtypes. Secondary amyloidosis used to be one of 
the most serious and fatal complications of JIA. The form of JIA is important; amyloidosis 
has been observed mainly in systemic and polyarticular forms. Amyloidosis is typically 
accompanied by elevated levels of SAA and CRP. The prevalence of secondary amyloidosis 
(SA) in juvenile idiopathic arthritis (JIA) varies between 1% and 10% (9-11) Secondary 
amyloidosis due to JIA has been decreasing dramatically in recent years, which is due to 
earlier recognition and better management of the disease and the introduction of new 
biologic agents. In this decade, amyloidosis is a rare entity in JIA. 
5.7 Other diseases 
Crohn’s and Behçet’s disease are known to be associated with secondary amyloidosis in 
severe cases. The mechanism may be speculated to be due to uncontrolled inflammation 
similar to that in monogenic autoinflammatory diseases. Also, sickle cell anemia, chronic 
granulomatous disease associated aspergillosis, and Hodgkin's disease are other diseases 
that have been very rarely associated with AA type of amyloidosis in children in the 
medical literature (71). 
6. Treatment 
The diagnosis of amyloidosis and typing are crucial for the patient. In practice, specific 
treatment of the underlying disorder, aiming to suppress the inflammatory activity is the 
major strategy. 
Treatment options of amyloidosis will be discussed in three main headings: 
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1. Reducing the production of amyloidogenic precursor protein (AA and AL amyloidosis) and 
enhancing the clearance of amyloidogenic precursor protein (Aβ2M amyloidosis) and trying to 
break down the amyloid deposits:  
Colchicine is the prototype drug that decreases production of amyloidogenic precursor 
protein. Biologic treatment, such as anti-TNF, anti-IL-1 therapy, may have a beneficial 
effect on the suppression of inflammation on amyloidosis. There are reports suggesting 
the effectiveness of anti-TNF and anti IL-1 antagonists on regression of secondary 
amyloidosis in FMF (72). 
2. Specific treatment strategies for secondary amyloidosis:  
New treatment options directed to affect the amyloid structure (e.g., diflunisal for 
hereditary amyloidosis) or to prevent fibrillogenesis (e.g., eprodisate for AA 
amyloidosis) or to weaken their structural stability (e.g., iododoxorubicin) are being 
investigated (73). Eprodisate inhibits polymerization of amyloid fibrils and deposition 
of the fibrils in tissues by interfere with interactions between amyloidogenic proteins 
and glycosaminoglycans. Eprodisate therapy slowed the progression of renal disease 
compared to placebo. However, the drug had no significant effect on progression to 
end-stage renal disease or risk of death (73). 
3. Renal replacement therapy. 
7. Conclusions  
The chronic inflammatuar and autoinflammatory diseases occur with persistant 
inflammation therefore they are the most common cause of reactive amyloidosis in children. 
Understanding the pathophysiology of this group of diseases will improve our data on the 
mechanisms of amyloid formation and therapy options. 
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